Patents by Inventor Sharon Mates

Sharon Mates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods
    Patent number: 11958852
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: April 16, 2024
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
  • NOVEL METHODS
    Publication number: 20240066030
    Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.
    Type: Application
    Filed: October 25, 2023
    Publication date: February 29, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
  • ORGANIC COMPOUNDS
    Publication number: 20240059687
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: August 17, 2023
    Publication date: February 22, 2024
    Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20240041871
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 8, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • NOVEL METHODS
    Publication number: 20240024334
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 11844757
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: December 19, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20230355616
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson’s disease or any combinations.
    Type: Application
    Filed: February 15, 2023
    Publication date: November 9, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • Organic compounds
    Patent number: 11773095
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: October 3, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • ORGANIC COMPOUNDS
    Publication number: 20230203037
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 29, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Peng LI, Lawrence P. WENNOGLE, Robert DAVIS
  • ORGANIC COMPOUNDS
    Publication number: 20230181576
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: September 9, 2020
    Publication date: June 15, 2023
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Wei YAO, Peng LI, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • Organic compounds
    Patent number: 11560382
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 24, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • ORGANIC COMPOUNDS
    Publication number: 20220372035
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 24, 2022
    Inventors: Peng LI, Hailin ZHENG, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • ORGANIC COMPOUNDS
    Publication number: 20220296591
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • Organic compounds
    Patent number: 11427587
    Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 30, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Hailin Zheng, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • Organic compounds
    Patent number: 11376249
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: July 5, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Wei Yao, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
  • METHODS OF TREATING ADDICTION
    Publication number: 20220088014
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, for use in methods for the treatment or prevention of opiate addiction relapse.
    Type: Application
    Filed: January 23, 2020
    Publication date: March 24, 2022
    Inventors: Peng LI, Wei YAO, Robert DAVIS, Sharon MATES, Kimberly VANOVER, Gretchen SNYDER
  • NOVEL COMPOUNDS AND METHODS
    Publication number: 20210371421
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Application
    Filed: August 18, 2021
    Publication date: December 2, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER, Lawrence WENNOGLE
  • NOVEL METHODS
    Publication number: 20210322433
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Application
    Filed: April 30, 2021
    Publication date: October 21, 2021
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
  • Compositions and methods
    Patent number: 11124514
    Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 21, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
  • Methods and compositions for sleep disorders and other disorders
    Patent number: RE48839
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: December 7, 2021
    Assignee: Intra-Cellular Therapies, Inc
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle